{"id":53907,"date":"2023-07-12T12:51:03","date_gmt":"2023-07-12T12:51:03","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=111338"},"modified":"2023-07-12T12:51:03","modified_gmt":"2023-07-12T12:51:03","slug":"recursion-announces-collaboration-and-50-million-investment-from-nvidia-to-accelerate-groundbreaking-foundation-models-in-ai-enabled-drug-discovery","status":"publish","type":"post","link":"https:\/\/southafricavoice.com\/recursion-announces-collaboration-and-50-million-investment-from-nvidia-to-accelerate-groundbreaking-foundation-models-in-ai-enabled-drug-discovery\/","title":{"rendered":"Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery"},"content":{"rendered":"
SALT LAKE CITY, TORONTO and MONTR\u00c9AL, July 12, 2023 (GLOBE NEWSWIRE) — Recursion<\/u><\/a> (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced a $50 million investment by NVIDIA<\/a>, which was executed as a private investment in public equity (PIPE). Recursion also announced plans to accelerate development of its AI foundation models for biology and chemistry, which, in collaboration with NVIDIA, it intends to optimize and distribute to biotechnology companies using NVIDIA cloud services.<\/p>\n \u201cOur collaboration with NVIDIA represents two best-in-class companies coming together to help solve one of the world\u2019s most difficult challenges, drug discovery,\u201d said Chris Gibson, Ph.D., Co-founder and CEO of Recursion. \u201cWith our powerful dataset and NVIDIA\u2019s accelerated computing capabilities, we intend to create groundbreaking foundation models in biology and chemistry at a scale unlike anything that has ever been released in the biological space.\u201d<\/p>\n Recursion plans to utilize its vast proprietary biological and chemical dataset, which exceeds 23 petabytes and 3 trillion searchable gene and compound relationships, to accelerate the training of foundation models on NVIDIA DGX Cloud<\/a> for possible commercial license\/release on BioNeMo, NVIDIA\u2019s cloud service for generative AI in drug discovery. NVIDIA will also help optimize and scale Recursion foundation models leveraging the NVIDIA AI stack and NVIDIA\u2019s full-stack computing expertise. BioNeMo<\/a> was announced earlier this year as a cloud service for generative AI in drug discovery, offering tools to quickly customize and deploy domain-specific, state-of-the-art biomolecular models at-scale through cloud APIs. Recursion anticipates using this software to support its internal pipeline as well as its current and future partners.<\/p>\n “Generative AI is a revolutionary tool to discover new medicines and treatments,\u201d said Jensen Huang, founder and CEO of NVIDIA. \u201cWe are delighted to collaborate with Recursion\u2019s world-class team, which is doing pioneering work in digital biology and chemistry with NVIDIA DGX and NVIDIA AI software to accelerate the development of the world\u2019s largest biomolecular generative AI models and speed drug discovery for biotech and pharmaceutical companies.\u201d<\/p>\n Recursion, through its recent acquisition of Valence Discovery<\/a>, aims to accelerate the development of new technologies to feed the biopharma industry, while simultaneously democratizing access to large-scale models that have maximum impact in drug discovery.<\/p>\n About Recursion<\/strong> Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive<\/u><\/a>, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montr\u00e9al and the San Francisco Bay Area. Learn more at www.Recursion.com<\/u><\/a>, or connect on Twitter<\/u><\/a> and LinkedIn<\/u><\/a>.<\/p>\n Media Contact<\/strong>
\nRecursion<\/u><\/a> (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world\u2019s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale \u2014 up to millions of wet lab experiments weekly \u2014 and massive computational scale \u2014 owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology, and chemistry to advance the future of medicine.<\/p>\n
\nMedia@Recursion.com<\/u><\/a><\/p>\n